All three items of MSD's Sinemet (Carvidopa-Levodopa) were withdrawn as of Monday. Accordingly, the same active ingredient containing product in Korea is Perkin by Myungin.

It is analyzed that Sinemet has lost its competitiveness since the launch of Stalevo (Carvidopa, Entacapone, Levodopa).

The MFDS dropped Sinemet CR, Sinemet 25/100 and Sinemet as of Thursday. Sinemet is a best-selling Parkinson's disease treatment approved in 1995. Since the launch of Stalevo, Sinemet's copyright has been changed and discontinued. In 2013, Sandoz Korea brought domestic copyright, and in 2019, it reported to the MFDS that it had been out of stock for a long time.

As a result, sales of out